Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.40), $0.10 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $3.17 million versus the consensus estimate of $4.74 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.